drugset / Trial / NCT05873426

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

NCT05873426

Phase 1 Completed 6 enrolled Guangdong Raynovent Biotech Co., Ltd
NaSingle-groupOpen-labelBasic science

Summary

This study is a single-center, open-label, and single-dose clinical study to evaluate the mass balance, biotransformation and pharmacokinetics of \[14C\]ZSP1273 in healthy Chinese male participants, revealing the overall pharmacokinetic characteristics of ZSP1273.

Timeline

Start
2023-03-25
Primary completion
2023-04-28
Completion
2023-04-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Onradivir Small molecule 600 mg Oral

Indications

No indication recorded.